A new study being presented at the meeting highlights the clinical value of targeted next-generation sequencing (NGS) for pathogen detection in bronchoalveolar lavage (BAL) samples from lung transplant recipients — using the MicroGenDX RespiKEY test.

Now available in Europe, RespiKEY combines targeted NGS and qPCR to identify bacteria, fungi and common antimicrobial resistance genes directly from patient samples, without relying on culture.

Attending Paris Lung 2026? Come and meet us to learn more about the BAL study, the supporting clinical evidence, and how RespiKEY can support the investigation of complex respiratory infections when conventional methods such as culture may be inconclusive.

We look forward to seeing you in Paris!